TRAIL and cancer therapy
- 1 May 2008
- journal article
- review article
- Published by Elsevier in Cancer Letters
- Vol. 263 (1) , 14-25
Abstract
No abstract availableKeywords
This publication has 76 references indexed in Scilit:
- Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAILNature Medicine, 2007
- Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptorProceedings of the National Academy of Sciences, 2006
- Molecular Determinants of Kinase Pathway Activation by Apo2 Ligand/Tumor Necrosis Factor-related Apoptosis-inducing LigandJournal of Biological Chemistry, 2005
- Radiotherapy Sensitization by Tumor-Specific TRAIL Gene Targeting Improves Survival of Mice Bearing Human Non–Small Cell Lung CancerClinical Cancer Research, 2005
- Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL‐R1 and TRAIL‐R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin‐ and bortezomib‐induced cell deathBritish Journal of Haematology, 2005
- HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivoBritish Journal of Cancer, 2005
- A Small Molecule Smac Mimic Potentiates TRAIL- and TNFα-Mediated Cell DeathScience, 2004
- Cell DeathCell, 2004
- Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Death-inducing Signaling Complex and Its Modulation by c-FLIP and PED/PEA-15 in Glioma CellsJournal of Biological Chemistry, 2002
- Safety and antitumor activity of recombinant soluble Apo2 ligandJournal of Clinical Investigation, 1999